Resverlogix is a leading epigenetics company, creating first-in-class small molecule therapeutics for BET inhibition.
Resverlogix Corp. (TSX: RVX) was established in 2000 and is developing apabetalone (RVX-208), a first-in-class, small molecule selective BET bromodomain inhibitor. Apabetalone is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, Orphan diseases (PNH), and Alzheimer's disease, while maintaining a well described safety profile.
Business Type: Nanotextile » | Biotechnology » | Electrotechnics » |
300, 4820 Richard Road SW